ESRF Proposed as a Framework for Interpreting Endometrial Cancer Treatment Resistance Through Epigenetic State Changes
Background
A literature review proposes interpreting endometrial cancer treatment response in relation not only to DNA mutations but also to changing epigenetic states. Published in International Journal of Molecular Sciences in May 2026, the paper’s central proposal is the Epigenetic State–Response Framework (ESRF), which synthesizes prior research. This proposal should be distinguished from results demonstrating reversal of resistance in new drug experiments or clinical trials involving patients.
Endometrial cancers can respond differently to treatment despite similar molecular features, and resistance may emerge during therapy. The authors explain that understanding these differences requires looking beyond genomic classification to the regulatory layers that control gene expression. These include DNA methylation, histone modifications, non-coding RNA (ncRNA), and chromatin remodeling. They can affect transcription without changing the DNA sequence, and the reversibility of some changes provides a rationale for studying whether treatment sensitivity can be restored.
Key findings
ESRF is a conceptual framework linking epigenetic changes with tumor function, treatment response, and intervention strategies. One representative example discussed in the review is promoter hypermethylation of the MLH1 gene, in which excessive methyl groups are added to a region that regulates gene expression. Suppression of MLH1 expression can impair DNA mismatch repair and lead to microsatellite instability. The review explains that these altered tumor characteristics affect immune recognition and response to immune checkpoint inhibitors. This should not be taken to mean that MLH1 methylation alone can definitively determine an individual patient’s treatment response.
The review also covers other regulatory pathways. Epigenetic suppression of the tumor suppressor gene PTEN is linked to activation of PI3K/AKT signaling, which contributes to cell survival and proliferation. Changes in estrogen and progesterone receptor expression are also factors affecting response to endocrine therapy. The authors bring these examples together to propose examining tumors not only in terms of fixed genotypes but also as functional states that change during treatment.
As treatment strategies, the authors review DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors. Drug examples in the review include the DNMT inhibitors azacitidine and decitabine, and the HDAC inhibitors vorinostat and romidepsin. They discuss the potential for combination therapy based on cited studies reporting restored gene expression, inhibited tumor growth in endometrial cancer models, and improved responses to other treatments. The review authors did not report having directly administered drugs and completely eliminated resistance.
Implications and outlook
One notable strategy is “epigenetic priming”: first modulating tumor state with epigenetic drugs or using them in combination with other treatments. The approach aims to alter the expression of genes involved in cell death or immune recognition, increasing the opportunity for subsequent treatment to work. However, sensitivity may not be restored, or toxicity may increase, depending on treatment timing, sequence, and dose. Mechanistic plausibility does not in itself establish efficacy in patients.
The review also proposes using DNA methylation markers and circulating RNA in blood to stratify patients and monitor them repeatedly during treatment. Epigenetic editing, which regulates expression at specific genomic loci, is discussed as an early-stage approach for studying resistance mechanisms and exploring precise interventions.
ESRF is a research framework connecting these targets and monitoring approaches; the paper did not validate predictive accuracy or survival benefit in a new patient cohort. Clinical application will require determining which markers capture changes in treatment response and whether adjusting treatment based on that information improves outcomes. Validation is still needed to bridge the gap between measuring epigenetic state and using those measurements to improve treatment decisions.
Sources: Full text indexed in Europe PMC, article DOI.
Summary: Addressing the therapeutic blind spots of endometrial cancer (EC), where tumors with identical genomic sub-types manifest highly divergent pharmacologic refractoriness, this study elucidates the dynamic macro-molecular networks driving post-treatment adaptation. Beyond static alterations, the framework integrates deep molecular registries of DNA methylation, histone modifications, and non-coding RNA (ncRNA) interactions under active therapeutic pressure. The platform demonstrates that epigenetic dysregulation enforces a highly plastic, reversible survival program. Strategically deploying targeted small-molecule histone deacetylase (HDAC) inhibitors computational-guided context successfully remodels spatial chromatin accessibility, reversing acquired resistance pathways and restoring drug sensitivity velocity across recalcitrant lineages, delivering a scalable baseline for multi-omic biomarker deployment and personalized combination stratification.
ESRF’s practical application is in designing further studies that connect epigenetic marker measurements with evaluation of combination therapies. For example, researchers could examine tumor methylation and hormone receptor status before treatment alongside changes in circulating DNA and RNA during treatment, then assess whether those changes are associated with declining treatment response. This could inform studies comparing marker-based patient selection or different sequences of epigenetic drug administration. ESRF itself, however, is not a validated treatment-selection tool and is not ready to serve directly as a prescribing criterion. Clinical use requires establishing how accurately measured changes reflect treatment response and whether the benefit of marker-guided intervention outweighs its toxicity.